Faculty from the Cutaneous Oncology Workshop answer practical questions spanning skin cancer prevention, diagnosis, treatment, and follow-up.
Poll|Articles|October 9, 2023
POLL: How Often Do You Collaborate With Gynecologists Regarding Genital Skin Cancers?
Author(s)Dermatology Times Staff
Listen
0:00 / 0:00
Key Takeaways
- Lichen sclerosus is associated with genital skin cancers, including vulvar and penile SCCs and genital melanomas.
- Approximately 4% of patients with lichen sclerosus may develop vulvar cancer.
Click here to answer this week's skin cancer poll.
Advertisement
How often do you collaborate with gynecologists regarding genital skin cancers?
The October issue of Dermatology Times recently reviewed in-depth the
- Lichen sclerosus, a noncancerous dermatologic condition, has been linked to genital skin cancers such as vulvar and penile squamous cell carcinomas (SCCs), as well as genital melanomas. About 4% of patients with lichen sclerosus may develop vulvar cancer.
- Genital cancers, including vaginal melanomas, vulvar melanoma, and penile melanoma, are relatively rare but can be associated with feelings of shame, stigma, and discomfort. It is crucial for clinicians to encourage patients to report unusual signs and symptoms to facilitate early diagnosis and treatment.
Due to the quality-of-life impacts of genital skin cancers, it can be beneficial for dermatologists and gynecologists to collaborate together when necessary to optimize patient care and outcomes.
What are your experiences with treating genital skin cancers or lichen sclerosus? Email us at
Advertisement
Related to this article
The inaugural workshop explored skin cancer care from prevention and diagnosis through systemic therapy, radiation, and multidisciplinary management.
The final session of the Cutaneous Oncology Workshop explored advances in systemic therapy, management of immunotherapy-related skin reactions, and the role of radiation.
At the Dermatology Times NP/PA Cutaneous Oncology Workshop in Tampa, Florida, Amit Om, MD, outlined why field-directed therapy is increasingly favored over lesion-directed treatment for actinic keratosis.
Faculty at the Dermatology Times Cutaneous Oncology Workshop addressed real-world questions on mole mapping, biopsy decisions, oral photoprotection, and actinic keratosis treatment.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
The expanded indication makes Ameluz with RhodoLED the first FDA-approved photodynamic therapy for the treatment of a skin cancer.
At the Cutaneous Oncology Workshop, faculty explored lesion recognition, surgical decision-making, risk stratification, and the evolving role of molecular testing.
Advertisement
Advertisement
Trending on Dermatology Times
1
Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol
2
Two-Year POETYK PsA-2 Data Show Durable Deucravacitinib Responses in Psoriatic Arthritis
3
Longer Topical JAK Inhibitor Treatment Linked to Vitiligo Improvement in Real-World Study
4
Sun Protection in Beauty Routines: Is SPF Makeup Enough?
5